Exact Mass: 521.2472
Exact Mass Matches: 521.2472
Found 500 metabolites which its exact mass value is equals to given mass value 521.2472
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Thienorphine
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
3alpha-[4-(beta-D-glucopyranosyloxy)-3-methoxy-5-(3-methyl-2-butenyl)benzoyloxy]tropane|merresectine D beta-D-glucoside
12-(2-methylaminobenzoyl)-4alpha-deoxyphorbaldehyde-13-acetate|12-<2-methylaminobenzoyl>-4alpha-deoxyphorbaldehyde-13-acetate
Phe Asn Ile Glu
Ala Glu Phe Arg
Ala Glu Arg Phe
Ala Phe Glu Arg
Ala Phe Arg Glu
Ala Arg Glu Phe
Ala Arg Phe Glu
Cys Phe Pro Arg
Cys Phe Arg Pro
Cys Ile Met Arg
Cys Ile Arg Met
Cys Ile Thr Trp
Cys Ile Trp Thr
Cys Leu Met Arg
Cys Leu Arg Met
Cys Leu Thr Trp
Cys Leu Trp Thr
Cys Met Ile Arg
Cys Met Leu Arg
Cys Met Arg Ile
Cys Met Arg Leu
Cys Pro Phe Arg
Cys Pro Arg Phe
Cys Arg Phe Pro
Cys Arg Ile Met
Cys Arg Leu Met
Cys Arg Met Ile
Cys Arg Met Leu
Cys Arg Pro Phe
Cys Thr Ile Trp
Cys Thr Leu Trp
Cys Thr Trp Ile
Cys Thr Trp Leu
Cys Trp Ile Thr
Cys Trp Leu Thr
Cys Trp Thr Ile
Cys Trp Thr Leu
Asp Phe Ile Gln
Asp Phe Leu Gln
Asp Phe Gln Ile
Asp Phe Gln Leu
Asp Ile Phe Gln
Asp Ile Gln Phe
Asp Lys Pro Tyr
Asp Lys Tyr Pro
Asp Leu Phe Gln
Asp Leu Gln Phe
Asp Pro Lys Tyr
Asp Pro Tyr Lys
Asp Gln Phe Ile
Asp Gln Phe Leu
Asp Gln Ile Phe
Asp Gln Leu Phe
Asp Tyr Lys Pro
Asp Tyr Pro Lys
Glu Ala Phe Arg
Glu Ala Arg Phe
Glu Phe Ala Arg
Glu Phe Ile Asn
Glu Phe Leu Asn
Glu Phe Asn Ile
Glu Phe Asn Leu
Glu Phe Gln Val
Glu Phe Arg Ala
Glu Phe Val Gln
Glu Ile Phe Asn
Glu Ile Asn Phe
Glu Leu Phe Asn
Glu Leu Asn Phe
Glu Asn Phe Ile
Glu Asn Phe Leu
Glu Asn Ile Phe
Glu Asn Leu Phe
Glu Gln Phe Val
Glu Gln Val Phe
Glu Arg Ala Phe
Glu Arg Phe Ala
Glu Val Phe Gln
Glu Val Gln Phe
Phe Ala Glu Arg
Phe Ala Arg Glu
Phe Cys Pro Arg
Phe Cys Arg Pro
Phe Asp Ile Gln
Phe Asp Leu Gln
Phe Asp Gln Ile
Phe Asp Gln Leu
Phe Glu Ala Arg
Phe Glu Ile Asn
Phe Glu Leu Asn
Phe Glu Asn Ile
Phe Glu Asn Leu
Phe Glu Gln Val
Phe Glu Arg Ala
Phe Glu Val Gln
Phe Gly Ile Trp
Phe Gly Leu Trp
Phe Gly Trp Ile
Phe Gly Trp Leu
Phe Ile Asp Gln
Phe Ile Glu Asn
Phe Ile Gly Trp
Phe Ile Asn Glu
Phe Ile Gln Asp
Phe Ile Trp Gly
Phe Lys Asn Asn
Phe Leu Asp Gln
Phe Leu Glu Asn
Phe Leu Gly Trp
Phe Leu Asn Glu
Phe Leu Gln Asp
Phe Leu Trp Gly
Phe Met Pro Gln
Phe Met Gln Pro
Phe Asn Glu Ile
Phe Asn Glu Leu
Phe Asn Lys Asn
Phe Asn Leu Glu
Phe Asn Asn Lys
Phe Pro Cys Arg
Phe Pro Met Gln
Phe Pro Gln Met
Phe Pro Arg Cys
Phe Gln Asp Ile
Phe Gln Asp Leu
Phe Gln Glu Val
Phe Gln Ile Asp
Phe Gln Leu Asp
Phe Gln Met Pro
Phe Gln Pro Met
Phe Gln Val Glu
Phe Arg Ala Glu
Phe Arg Cys Pro
Phe Arg Glu Ala
Phe Arg Pro Cys
Phe Val Ala Trp
Phe Val Glu Gln
Phe Val Gln Glu
Phe Val Trp Ala
Phe Trp Ala Val
Phe Trp Gly Ile
Phe Trp Gly Leu
Phe Trp Ile Gly
Phe Trp Leu Gly
Phe Trp Val Ala
Gly Phe Ile Trp
Gly Phe Leu Trp
Gly Phe Trp Ile
Gly Phe Trp Leu
Gly Ile Phe Trp
Gly Ile Trp Phe
Gly Leu Phe Trp
Gly Leu Trp Phe
Gly Trp Phe Ile
Gly Trp Phe Leu
Gly Trp Ile Phe
Gly Trp Leu Phe
His His Gln Thr
His His Thr Gln
His Gln His Thr
His Gln Thr His
His Thr His Gln
His Thr Gln His
Ile Cys Met Arg
Ile Cys Arg Met
Ile Cys Thr Trp
Ile Cys Trp Thr
Ile Asp Phe Gln
Ile Asp Gln Phe
Ile Glu Phe Asn
Ile Glu Asn Phe
Ile Phe Asp Gln
Ile Phe Glu Asn
Ile Phe Gly Trp
Ile Phe Asn Glu
Ile Phe Gln Asp
Ile Phe Trp Gly
Ile Gly Phe Trp
Ile Gly Trp Phe
Ile Met Cys Arg
Ile Met Met Gln
Ile Met Gln Met
Ile Met Arg Cys
Ile Asn Glu Phe
Ile Asn Phe Glu
Ile Gln Asp Phe
Ile Gln Phe Asp
Ile Gln Met Met
Ile Arg Cys Met
Ile Arg Met Cys
Ile Thr Cys Trp
Ile Thr Trp Cys
Ile Trp Cys Thr
Ile Trp Phe Gly
Ile Trp Gly Phe
Ile Trp Thr Cys
Lys Asp Pro Tyr
Lys Asp Tyr Pro
Lys Phe Asn Asn
Lys Asn Phe Asn
Lys Asn Asn Phe
Lys Pro Asp Tyr
Lys Pro Tyr Asp
Lys Tyr Asp Pro
Lys Tyr Pro Asp
Leu Cys Met Arg
Leu Cys Arg Met
Leu Cys Thr Trp
Leu Cys Trp Thr
Leu Asp Phe Gln
Leu Asp Gln Phe
Leu Glu Phe Asn
Leu Glu Asn Phe
Leu Phe Asp Gln
Leu Phe Glu Asn
Leu Phe Gly Trp
Leu Phe Asn Glu
Leu Phe Gln Asp
Leu Phe Trp Gly
Leu Gly Phe Trp
Leu Gly Trp Phe
Leu Met Cys Arg
Leu Met Met Gln
Leu Met Gln Met
Leu Met Arg Cys
Leu Asn Glu Phe
Leu Asn Phe Glu
Leu Gln Asp Phe
Leu Gln Phe Asp
Leu Gln Met Met
Leu Arg Cys Met
Leu Arg Met Cys
Leu Thr Cys Trp
Leu Thr Trp Cys
Leu Trp Cys Thr
Leu Trp Thr Cys
Met Cys Ile Arg
Met Cys Leu Arg
Met Cys Arg Ile
Met Cys Arg Leu
Met Phe Pro Gln
Met Phe Gln Pro
Met Ile Cys Arg
Met Ile Met Gln
Met Ile Gln Met
Met Ile Arg Cys
Met Leu Cys Arg
Met Leu Met Gln
Met Leu Gln Met
Met Leu Arg Cys
Met Met Ile Gln
Met Met Leu Gln
Met Met Gln Ile
Met Met Gln Leu
Met Pro Phe Gln
Met Pro Gln Phe
Met Gln Phe Pro
Met Gln Ile Met
Met Gln Leu Met
Met Gln Met Ile
Met Gln Met Leu
Met Gln Pro Phe
Met Arg Cys Ile
Met Arg Cys Leu
Met Arg Ile Cys
Met Arg Leu Cys
Met Ser Val Trp
Met Ser Trp Val
Met Val Ser Trp
Met Val Trp Ser
Met Trp Ser Val
Met Trp Val Ser
Asn Glu Phe Ile
Asn Glu Phe Leu
Asn Glu Ile Phe
Asn Glu Leu Phe
Asn Phe Glu Ile
Asn Phe Glu Leu
Asn Phe Ile Glu
Asn Phe Lys Asn
Asn Phe Leu Glu
Asn Phe Asn Lys
Asn Ile Glu Phe
Asn Ile Phe Glu
Asn Lys Phe Asn
Asn Lys Asn Phe
Asn Leu Glu Phe
Asn Leu Phe Glu
Asn Asn Phe Lys
Asn Asn Lys Phe
Pro Cys Phe Arg
Pro Cys Arg Phe
Pro Asp Lys Tyr
Pro Asp Tyr Lys
Pro Phe Cys Arg
Pro Phe Met Gln
Pro Phe Gln Met
Pro Phe Arg Cys
Pro Lys Asp Tyr
Pro Lys Tyr Asp
Pro Met Phe Gln
Pro Met Gln Phe
Pro Gln Phe Met
Pro Gln Met Phe
Pro Arg Cys Phe
Pro Arg Phe Cys
Pro Arg Ser Tyr
Pro Arg Tyr Ser
Pro Ser Arg Tyr
Pro Ser Tyr Arg
Pro Tyr Asp Lys
Pro Tyr Lys Asp
Pro Tyr Arg Ser
Pro Tyr Ser Arg
Gln Asp Phe Ile
Gln Asp Phe Leu
Gln Asp Ile Phe
Gln Asp Leu Phe
Gln Glu Phe Val
Gln Glu Val Phe
Gln Phe Asp Ile
Gln Phe Asp Leu
Gln Phe Glu Val
Gln Phe Ile Asp
Gln Phe Leu Asp
Gln Phe Met Pro
Gln Phe Pro Met
Gln Phe Val Glu
Gln His His Thr
Gln His Thr His
Gln Ile Asp Phe
Gln Ile Phe Asp
Gln Ile Met Met
Gln Leu Asp Phe
Gln Leu Phe Asp
Gln Leu Met Met
Gln Met Phe Pro
Gln Met Ile Met
Gln Met Leu Met
Gln Met Met Ile
Gln Met Met Leu
Gln Met Pro Phe
Gln Pro Phe Met
Gln Pro Met Phe
Gln Thr His His
Gln Val Glu Phe
Gln Val Phe Glu
Arg Ala Glu Phe
Arg Ala Phe Glu
Arg Cys Phe Pro
Arg Cys Ile Met
Arg Cys Leu Met
Arg Cys Met Ile
Arg Cys Met Leu
Arg Cys Pro Phe
Arg Glu Ala Phe
Arg Glu Phe Ala
Arg Phe Ala Glu
Arg Phe Cys Pro
Arg Phe Glu Ala
Arg Phe Pro Cys
Arg Ile Cys Met
Arg Ile Met Cys
Arg Leu Cys Met
Arg Leu Met Cys
Arg Met Cys Ile
Arg Met Cys Leu
Arg Met Ile Cys
Arg Met Leu Cys
Arg Pro Cys Phe
Arg Pro Phe Cys
Arg Pro Ser Tyr
Arg Pro Tyr Ser
Arg Ser Pro Tyr
Arg Ser Tyr Pro
Arg Tyr Pro Ser
Arg Tyr Ser Pro
Ser Met Val Trp
Ser Met Trp Val
Ser Pro Arg Tyr
Ser Pro Tyr Arg
Ser Arg Pro Tyr
Ser Arg Tyr Pro
Ser Val Met Trp
Ser Val Trp Met
Ser Trp Met Val
Ser Trp Val Met
Ser Tyr Pro Arg
Ser Tyr Arg Pro
Thr Cys Ile Trp
Thr Cys Leu Trp
Thr Cys Trp Ile
Thr Cys Trp Leu
Thr His His Gln
Thr His Gln His
Thr Ile Cys Trp
Thr Ile Trp Cys
Thr Leu Cys Trp
Thr Leu Trp Cys
Thr Gln His His
Thr Trp Cys Ile
Thr Trp Cys Leu
Thr Trp Ile Cys
Thr Trp Leu Cys
Val Glu Phe Gln
Val Glu Gln Phe
Val Phe Glu Gln
Val Phe Gln Glu
Val Met Ser Trp
Val Met Trp Ser
Val Gln Glu Phe
Val Gln Phe Glu
Val Ser Met Trp
Val Ser Trp Met
Val Trp Met Ser
Val Trp Ser Met
Trp Cys Ile Thr
Trp Cys Leu Thr
Trp Cys Thr Ile
Trp Cys Thr Leu
Trp Phe Gly Leu
Trp Phe Ile Gly
Trp Phe Leu Gly
Trp Phe Val Ala
Trp Gly Phe Leu
Trp Gly Ile Phe
Trp Gly Leu Phe
Trp Ile Cys Thr
Trp Ile Phe Gly
Trp Ile Thr Cys
Trp Leu Cys Thr
Trp Leu Thr Cys
Trp Met Ser Val
Trp Met Val Ser
Trp Ser Met Val
Trp Ser Val Met
Trp Thr Cys Ile
Trp Thr Cys Leu
Trp Thr Ile Cys
Trp Thr Leu Cys
Trp Val Met Ser
Trp Val Ser Met
Tyr Asp Lys Pro
Tyr Asp Pro Lys
Tyr Lys Asp Pro
Tyr Lys Pro Asp
Tyr Pro Asp Lys
Tyr Pro Lys Asp
Tyr Pro Arg Ser
Tyr Pro Ser Arg
Tyr Arg Pro Ser
Tyr Arg Ser Pro
Tyr Ser Pro Arg
Tyr Ser Arg Pro
CP-640186 hydrochloride
CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation[1][2].
(3R)-2-[(R)-tert-butylsulfinyl]-N-ethyl-3-(2-hydroxyethyl)-4-[3-(3-methoxyphenyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-8-(4-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(4-methoxyphenyl)phenyl]-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-methoxyphenyl)phenyl]-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
N-[[(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-1,3-benzodioxole-5-carboxamide
(1R)-N2-cyclopentyl-N1-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxyspiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]-1,2-dicarboxamide
1-[(1R)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-cyclopropylethanone
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(4-methoxyphenyl)phenyl]-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(3S)-2-[(S)-tert-butylsulfinyl]-N-ethyl-3-(2-hydroxyethyl)-4-[3-(3-methoxyphenyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(3-methoxyphenyl)phenyl]-N,N-dimethyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
(1S)-N2-cyclopentyl-N1-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxyspiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]-1,2-dicarboxamide
1-[(1S)-2-[(2-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-2-cyclopropylethanone
Exarafenib
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].